Amgen Enbrel Rhode Island Facility To Get FDA Inspection In Early November
Executive Summary
FDA will inspect Amgen's Enbrel Rhode Island manufacturing plant in early November, Amgen said during its third quarter earnings call on Oct. 23
You may also be interested in...
Amgen Enbrel 50 Mg Syringe Expected To Simplify Dosing For Psoriasis
Amgen expects to receive approval by year-end for an Enbrel 50 mg pre-filled syringe that could simplify dosing of the TNF inhibitor for treatment of plaque psoriasis and other indications
Amgen Enbrel 50 Mg Syringe Expected To Simplify Dosing For Psoriasis
Amgen expects to receive approval by year-end for an Enbrel 50 mg pre-filled syringe that could simplify dosing of the TNF inhibitor for treatment of plaque psoriasis and other indications
Amgen/Wyeth Enbrel Supplies Replenished With Rhode Island Plant Approval
Amgen and Wyeth are in a position to resume full promotion of the rheumatoid arthritis agent Enbrel following FDA approval of a new manufacturing site in Rhode Island